Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer—From Early Detection to Prognosis DOI Open Access

Natalia Jaszek,

Alicja Bogdanowicz,

Jan Siwiec

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7159 - 7159

Опубликована: Ноя. 26, 2024

Bladder cancer (BC) currently ranks as the 9th most common worldwide. It is characterised by very high rates of recurrence and metastasis. Most cases BC are urothelial origin, due to its ability penetrate muscle tissue, divided into non-muscle-invasive (NMIBC) muscle-invasive (MIBC). The current diagnosis still based primarily on invasive cystoscopy, which an expensive method that carries a risk various complications. Urine sediment cytology often used complementary test, biggest drawback low sensitivity concerning detection at early stages, crucial for prompt implementation appropriate treatment. Therefore, there great need develop innovative diagnostic techniques would enable accurate prognosis BC. Great potential in this regard shown epigenetic changes, possible observe long before onset clinical symptoms disease. In addition, these changes can be detected readily available biological material, such urine or blood, indicating possibility constructing non-invasive tests. Over past few years, many studies have emerged using alterations novel prognostic biomarkers This review provides update promising DNA methylation expression levels selected non-coding RNAs (ncRNAs), taking account latest literature data.

Язык: Английский

The latest applications of exosome-mediated drug delivery in anticancer therapies DOI

Zhiwei Wen,

Wei Zhang, Wei Wu

и другие.

Colloids and Surfaces B Biointerfaces, Год журнала: 2025, Номер 249, С. 114500 - 114500

Опубликована: Янв. 6, 2025

Язык: Английский

Процитировано

0

Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics DOI Creative Commons

Tomoaki Hara,

Sikun Meng, Aya Hasan Alshammari

и другие.

Diagnostics, Год журнала: 2025, Номер 15(5), С. 628 - 628

Опубликована: Март 5, 2025

Cancer cells exhibit abnormal behavior compared to normal cells. They ignore growth arrest signals such as contact inhibition, a mechanism that stops their proliferation when they collide with surrounding cells, and proliferate in an uncontrolled manner, destroying tissue. Early detection treatment of cancer are therefore important for healthy longevity. differ from characteristic gene expression due abnormalities. markers reflect these characteristics have been searched applied diagnosis. Although analysis blood antigens has the main method, further development diagnostic system is needed early cancer. Next-generation sequencers improved technology, making it possible analyze detailed nucleic acid molecules or urine. In addition, release extracellular vesicles, exosomes, which known contain may serve markers. This review summarizes latest findings on exosomal

Язык: Английский

Процитировано

0

Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts DOI Creative Commons
Hui Li,

Chuannan Sun,

Bin Luo

и другие.

Biomolecules, Год журнала: 2024, Номер 14(8), С. 954 - 954

Опубликована: Авг. 6, 2024

Cardiac mesoderm enhancer-associated non-coding RNA (CARMN), an evolutionarily conserved long (lncRNA), serves as the host gene for miR143/145 cluster. It plays a crucial role in cardiovascular cell differentiation and maintenance of vascular smooth muscle (VSMC) homeostasis, which are vital normal physiological processes. Specifically, CARMN is associated with pathological progression diseases such atherosclerosis, abdominal aortic aneurysm, chronic heart failure. Moreover, it acts tumor suppressor various cancers, including hepatocellular carcinoma, bladder cancer, breast highlighting its potential beneficial biomarker therapeutic target. This review provides detailed examination roles CARMN, evolutionary conservation, expression patterns, regulatory mechanisms. also outlines significant implications diagnosis, prognosis, treatment these diseases, underscoring need further translational research to exploit clinical potential.

Язык: Английский

Процитировано

1

Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host? DOI Creative Commons
Jun Zou, Baisheng Xu,

Peiyue Luo

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Ноя. 19, 2024

In recent years, the role of gut microbiota (GM) in bladder cancer has attracted significant attention. Research indicates that GM not only contributes to carcinogenesis but also influences efficacy adjuvant therapies for cancer. Despite this, interventions targeting have been widely employed prevention and treatment cancer, mainly due incomplete understanding complex interactions between host flora. Simultaneously, aberrantly expressed non-coding RNAs (ncRNAs) frequently associated with playing crucial roles processes such as cell proliferation, invasion, drug resistance. It is known regulation GM-mediated pathophysiological partly regulated through epigenetic pathways. At same time, ncRNAs are increasingly regarded signaling molecules involved regulation. Accordingly, this review analyzes closely related context occurrence treatment, summarizes their interaction cancer-related phenotypes. The aim delineate a regulatory network provide new perspective study

Язык: Английский

Процитировано

0

MALAT1 and BCYRN1 lncRNAs expression in patients with breast cancer from Northwest Iran DOI
Alireza Ahmadi, Amin Moqadami, Mohammad Khalaj‐Kondori

и другие.

Human Gene, Год журнала: 2024, Номер 43, С. 201370 - 201370

Опубликована: Дек. 12, 2024

Язык: Английский

Процитировано

0

LncRNA BC200 promotes the development of EBV-associated nasopharyngeal carcinoma by competitively binding to miR-6834-5p to upregulate TYMS expression DOI

Senmiao Zhang,

Na Liu,

Pengfei Cao

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 278, С. 134837 - 134837

Опубликована: Авг. 22, 2024

Язык: Английский

Процитировано

0

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer—From Early Detection to Prognosis DOI Open Access

Natalia Jaszek,

Alicja Bogdanowicz,

Jan Siwiec

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(23), С. 7159 - 7159

Опубликована: Ноя. 26, 2024

Bladder cancer (BC) currently ranks as the 9th most common worldwide. It is characterised by very high rates of recurrence and metastasis. Most cases BC are urothelial origin, due to its ability penetrate muscle tissue, divided into non-muscle-invasive (NMIBC) muscle-invasive (MIBC). The current diagnosis still based primarily on invasive cystoscopy, which an expensive method that carries a risk various complications. Urine sediment cytology often used complementary test, biggest drawback low sensitivity concerning detection at early stages, crucial for prompt implementation appropriate treatment. Therefore, there great need develop innovative diagnostic techniques would enable accurate prognosis BC. Great potential in this regard shown epigenetic changes, possible observe long before onset clinical symptoms disease. In addition, these changes can be detected readily available biological material, such urine or blood, indicating possibility constructing non-invasive tests. Over past few years, many studies have emerged using alterations novel prognostic biomarkers This review provides update promising DNA methylation expression levels selected non-coding RNAs (ncRNAs), taking account latest literature data.

Язык: Английский

Процитировано

0